24 April 2009

Graft vs. host skin disease



Graft vs. host skin disease

Chronic graft vs. host disease
A paradigm for the study of skin disease co-morbidity

by: Dermatotoxicity session
Society for Investigative Dermatology
Burden of Skin Disease Co-Morbidity Conference


Edward W. Cowen, MD, MHSc
Dermatology Branch, CCR
National Cancer Institute, NIH


Objectives


* Epidemiology of chronic graft-versus-host disease (cGVHD)
* Brief review of skin and other organ manifestations

* Barriers to effective management and a few (possible) solutions

Graft-versus-host disease (GVHD)

* Allogeneic hematopoietic stem cell transplantation (Allo-SCT)

* Autologous-SCT, solid organ, transfusion-related

* Host: Patient
o Hematopoietic ablation (chemotherapy/radiation)

* Graft: Donor stem cells
o Bone marrow
o Cord blood
o Peripheral blood (PBSCT)
+ Mobilization (Filgrastim;Neupogen®) - apheresis

* NIH Clinical Center
o 100+ allogeneic transplants/year

* 15,000 allogeneic transplants/year

* Indications
o Hematologic malignancies
o Primary immunodeficiencies
o Inherited enzymatic defects
o Solid tumors
o Autoimmune disease

Diseases treated by transplantation

Chronic GVHD
Incidence of chronic GVHD
Homeostasis
Hematopoeitic chimerism
All other tissues
All hematopoeitic cells
Hematopoeitic chimerism
Lymphocyte Infusion
Graft vs. leukemia/
Graft vs. tumor effect
Hematopoeitic cells
Other tissues
Homeostasis
Immunosuppressive therapy
Recurrent malignancy,
Opportunistic infection
Hematopoeitic cells
cGVHD: non-dermatologic manifestations
Erythema and ulcers
Viral or fungal infection
Abnormal motility
Secondary viral or fungal infection
Bronchiolitis obliterans
Dryness, strictures
Myasthenia gravis
cGVHD: a polymorphous skin disorder
Epidermal cGVHD
Dermal cGVHD
Subcutaneous cGVHD
cGVHD is a cutaneous mimic
Co-morbidity of cutaneous cGVHD
cGVHD: management
cGVHD salvage therapy
cGVHD: (barriers to) management
Barriers to effective management
Possible solutions
Barriers to effective management
Possible solutions
Chronic Cutaneous GVHD Skin Assessment
Erosion vs. Ulceration
Biology Blood Marrow Transplant 2005-6.

cGVHD
Hematology/Oncology
Dermatology
Dentistry/Oral Surgery
Rheumatology
Infectious Diseases
Ophthalmology
Pain/Palliative Care
Nutritional Support
Rehabilitation Medicine
NIH: multidisciplinary approach to cGVHD
Natural history of disease
Montelukast (Singulair®)
Extracorporal photopheresis
Imatinib for sclerotic cGVHD
DNA Microarray analysis
High-resolution MRI/US
Topical thalidomide
Cyclosporine implants
NIH National Consensus Guidelines for cGVHD Clinical Trials and Management
Barriers to effective management
Possible solutions
A final thought

Graft vs. host skin disease.ppt

0 comments:

All links posted here are collected from various websites. No video or powerpoint files are uploaded on this blog. If you are the original author and do not wish to display your content on this blog please Email me anandkumarreddy at gmail dot com I will remove it. The contents of this blog are meant for educational purpose and not for commercial use. If you use any content give due credit to the original author.

This site uses cookies from Google to deliver its services, to personalise ads and to analyse traffic. Information about your use of this site is shared with Google. By using this site, you agree to its use of cookies.

  © Blogger templates Newspaper III by Ourblogtemplates.com 2008

Back to TOP